MX367121B - Composición sólida estable de inmunosupresores. - Google Patents

Composición sólida estable de inmunosupresores.

Info

Publication number
MX367121B
MX367121B MX2013008994A MX2013008994A MX367121B MX 367121 B MX367121 B MX 367121B MX 2013008994 A MX2013008994 A MX 2013008994A MX 2013008994 A MX2013008994 A MX 2013008994A MX 367121 B MX367121 B MX 367121B
Authority
MX
Mexico
Prior art keywords
stable solid
immunosuppressants
solid composition
pharmaceutically acceptable
poloxamers
Prior art date
Application number
MX2013008994A
Other languages
English (en)
Other versions
MX2013008994A (es
Inventor
Amezcua Amezcua Federico
Original Assignee
Laboratorio Raam De Sahuayo S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio Raam De Sahuayo S A De C V filed Critical Laboratorio Raam De Sahuayo S A De C V
Priority to MX2013008994A priority Critical patent/MX367121B/es
Publication of MX2013008994A publication Critical patent/MX2013008994A/es
Priority to CA2946151A priority patent/CA2946151C/en
Priority to PCT/MX2014/000113 priority patent/WO2015016694A1/es
Priority to US14/909,261 priority patent/US20160235722A1/en
Priority to EP14832892.5A priority patent/EP3028693A4/en
Publication of MX367121B publication Critical patent/MX367121B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica sólida estable que comprende 1) uno o más agentes inmunosupresores y/o sus sales farmacéuticamente aceptables; 2) una mezcla estabilizadora que comprende i) vitamina E oleosa, ii) 1-leucina, y iii) uno o más poloxameros; y, 3) uno o más excipientes farmacéuticamente aceptables, contenidos en al menos una unidad de dosificación.
MX2013008994A 2013-08-02 2013-08-02 Composición sólida estable de inmunosupresores. MX367121B (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2013008994A MX367121B (es) 2013-08-02 2013-08-02 Composición sólida estable de inmunosupresores.
CA2946151A CA2946151C (en) 2013-08-02 2014-07-24 Stable solid immunosuppressor composition
PCT/MX2014/000113 WO2015016694A1 (es) 2013-08-02 2014-07-24 Composición sólida estable de inmunosupresores
US14/909,261 US20160235722A1 (en) 2013-08-02 2014-07-24 Stable Solid Immunosuppressor Composition
EP14832892.5A EP3028693A4 (en) 2013-08-02 2014-07-24 Stable solid immunosuppressor composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013008994A MX367121B (es) 2013-08-02 2013-08-02 Composición sólida estable de inmunosupresores.

Publications (2)

Publication Number Publication Date
MX2013008994A MX2013008994A (es) 2014-03-24
MX367121B true MX367121B (es) 2019-08-06

Family

ID=50935219

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008994A MX367121B (es) 2013-08-02 2013-08-02 Composición sólida estable de inmunosupresores.

Country Status (5)

Country Link
US (1) US20160235722A1 (es)
EP (1) EP3028693A4 (es)
CA (1) CA2946151C (es)
MX (1) MX367121B (es)
WO (1) WO2015016694A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1939302A (en) * 1929-04-12 1933-12-12 Edward B Benjamin Apparatus for and art of carburation
ES2173978T3 (es) * 1994-10-26 2002-11-01 Novartis Ag Utilizacion de un alcohol graso insaturado.
CN100581545C (zh) 2005-09-29 2010-01-20 福建省微生物研究所 西罗莫司药物组合物及制备方法
PT2279731E (pt) * 2008-04-23 2013-08-30 Farmasierra Mfg S L Composição farmacêutica melhorada contendo ibuprofeno e codeína
US8001790B2 (en) * 2008-08-11 2011-08-23 Mitsubishi Heavy Industries, Ltd. Gas turbine
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
US9101541B2 (en) 2010-04-28 2015-08-11 Cadila Healthcare Limited Stable solid pharmaceutical matrix compositions of sirolimus

Also Published As

Publication number Publication date
WO2015016694A1 (es) 2015-02-05
CA2946151C (en) 2021-05-25
US20160235722A1 (en) 2016-08-18
MX2013008994A (es) 2014-03-24
CA2946151A1 (en) 2015-02-05
EP3028693A1 (en) 2016-06-08
EP3028693A4 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
MX2015009773A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
EA201792591A1 (ru) Фармацевтические препараты
MX2015009785A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2015009778A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
PH12018502524B1 (en) Physiologically balanced injectable formulations of fosnetupitant
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
MX2020012989A (es) Agente terapeutico para la fibrosis.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
MX2013008994A (es) Composicion solida estable de inmunosupresores.
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
IN2013MU03370A (es)
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
EA201691422A1 (ru) Перорально распадающиеся таблетированные составы мемантина
IN2013MU02015A (es)
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
MX2016010104A (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria.
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
MX2019003229A (es) Formulaciones liquidas estables.

Legal Events

Date Code Title Description
FG Grant or registration